Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
ADXN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.51 - $12.05
Previous CloseN/A
Volume26.36K
Average Volume (3M)42.59K
Market Cap
$15.05M
Enterprise ValueN/A
Total Cash (Recent Filing)$2.83M
Total Debt (Recent Filing)$40.20K
Price to Earnings (P/E)0.8
Beta0.32
Next Earnings
Sep 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,536,287
10 Day Avg. Volume11,282
30 Day Avg. Volume42,587
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.50Price Target Upside-4.92% Downside
Rating ConsensusHold
Number of Analyst Covering0
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $6.51 and its highest was $12.05 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $15.05M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Sep 30, 2025 which is today.
How were Addex Therapeutics’s earnings last quarter?
Currently, no data Available
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,536,287 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Addex Therapeutics?
Among the largest hedge funds holding Addex Therapeutics’s share is New Leaf Venture Partners, L.L.C.. It holds Addex Therapeutics’s shares valued at 0.
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
ADXN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic partnerships and advancements in drug development programs, notably the successful Series A financing for Neurosterix and progress in the GABAB PAM program. However, challenges remain with decreased income and cash limitations for unpartnered programs, indicating a balanced outlook.View all ADXN earnings summariesTechnical Analysis
Plus Therapeutics
―
Eterna Therapeutics
―
Minerva Neurosciences
―
GeoVax Labs
―
Moleculin Biotech
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.07% Other Institutional Investors
99.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---